0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Inherited Retinal Disease Treatment Market Research Report 2025
Published Date: May 2025
|
Report Code: QYRE-Auto-13B15777
Home | Market Reports | Health| Vision Care
Global Inherited Retinal Disease Treatment Market Research Report 2023
BUY CHAPTERS

Global Inherited Retinal Disease Treatment Market Research Report 2025

Code: QYRE-Auto-13B15777
Report
May 2025
Pages:98
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Inherited Retinal Disease Treatment Market

The global market for Inherited Retinal Disease Treatment was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
North American market for Inherited Retinal Disease Treatment is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Inherited Retinal Disease Treatment is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Inherited Retinal Disease Treatment include Spark Therapeutics, Novartis, Okuvision, NIDEK, Invitae, ZEISS INTERNATIONAL, MeiraGTx, Neurosoft, Astellas Pharma, Bionic Vision Technologies, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Inherited Retinal Disease Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Inherited Retinal Disease Treatment.
The Inherited Retinal Disease Treatment market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Inherited Retinal Disease Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Inherited Retinal Disease Treatment manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Inherited Retinal Disease Treatment Market Report

Report Metric Details
Report Name Inherited Retinal Disease Treatment Market
Segment by Type
Segment by Application
  • Hospital
  • Clinic
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Spark Therapeutics, Novartis, Okuvision, NIDEK, Invitae, ZEISS INTERNATIONAL, MeiraGTx, Neurosoft, Astellas Pharma, Bionic Vision Technologies, Coave Therapeutics, GenSight Biologics, Ionis Pharmaceuticals, IVERIC BIO, Johnson & Johnson, LKC Technologies, Santen Pharmaceutical, He Eye Hospital, Bgi Genomics
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Inherited Retinal Disease Treatment manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Inherited Retinal Disease Treatment in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

Who are the main players in the Inherited Retinal Disease Treatment Market report?

Ans: The main players in the Inherited Retinal Disease Treatment Market are Spark Therapeutics, Novartis, Okuvision, NIDEK, Invitae, ZEISS INTERNATIONAL, MeiraGTx, Neurosoft, Astellas Pharma, Bionic Vision Technologies, Coave Therapeutics, GenSight Biologics, Ionis Pharmaceuticals, IVERIC BIO, Johnson & Johnson, LKC Technologies, Santen Pharmaceutical, He Eye Hospital, Bgi Genomics

What are the Application segmentation covered in the Inherited Retinal Disease Treatment Market report?

Ans: The Applications covered in the Inherited Retinal Disease Treatment Market report are Hospital, Clinic

What are the Type segmentation covered in the Inherited Retinal Disease Treatment Market report?

Ans: The Types covered in the Inherited Retinal Disease Treatment Market report are Gene Therapy, Artificial Retina, Neuroprotectant

Recommended Reports

Retinal Disease Treatments

Ophthalmic Devices & Solutions

Eye Genetic & Neuro Diseases

1 Inherited Retinal Disease Treatment Market Overview
1.1 Product Definition
1.2 Inherited Retinal Disease Treatment by Type
1.2.1 Global Inherited Retinal Disease Treatment Market Value Comparison by Type (2024 VS 2031)
1.2.2 Gene Therapy
1.2.3 Artificial Retina
1.2.4 Neuroprotectant
1.3 Inherited Retinal Disease Treatment by Application
1.3.1 Global Inherited Retinal Disease Treatment Market Value by Application (2024 VS 2031)
1.3.2 Hospital
1.3.3 Clinic
1.4 Global Inherited Retinal Disease Treatment Market Size Estimates and Forecasts
1.4.1 Global Inherited Retinal Disease Treatment Revenue 2020-2031
1.4.2 Global Inherited Retinal Disease Treatment Sales 2020-2031
1.4.3 Global Inherited Retinal Disease Treatment Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Inherited Retinal Disease Treatment Market Competition by Manufacturers
2.1 Global Inherited Retinal Disease Treatment Sales Market Share by Manufacturers (2020-2025)
2.2 Global Inherited Retinal Disease Treatment Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Inherited Retinal Disease Treatment Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Inherited Retinal Disease Treatment, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Inherited Retinal Disease Treatment, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Inherited Retinal Disease Treatment, Product Type & Application
2.7 Global Key Manufacturers of Inherited Retinal Disease Treatment, Date of Enter into This Industry
2.8 Global Inherited Retinal Disease Treatment Market Competitive Situation and Trends
2.8.1 Global Inherited Retinal Disease Treatment Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Inherited Retinal Disease Treatment Players Market Share by Revenue
2.8.3 Global Inherited Retinal Disease Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Inherited Retinal Disease Treatment Market Scenario by Region
3.1 Global Inherited Retinal Disease Treatment Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Inherited Retinal Disease Treatment Sales by Region: 2020-2031
3.2.1 Global Inherited Retinal Disease Treatment Sales by Region: 2020-2025
3.2.2 Global Inherited Retinal Disease Treatment Sales by Region: 2026-2031
3.3 Global Inherited Retinal Disease Treatment Revenue by Region: 2020-2031
3.3.1 Global Inherited Retinal Disease Treatment Revenue by Region: 2020-2025
3.3.2 Global Inherited Retinal Disease Treatment Revenue by Region: 2026-2031
3.4 North America Inherited Retinal Disease Treatment Market Facts & Figures by Country
3.4.1 North America Inherited Retinal Disease Treatment Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Inherited Retinal Disease Treatment Sales by Country (2020-2031)
3.4.3 North America Inherited Retinal Disease Treatment Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe Inherited Retinal Disease Treatment Market Facts & Figures by Country
3.5.1 Europe Inherited Retinal Disease Treatment Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Inherited Retinal Disease Treatment Sales by Country (2020-2031)
3.5.3 Europe Inherited Retinal Disease Treatment Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Inherited Retinal Disease Treatment Market Facts & Figures by Region
3.6.1 Asia Pacific Inherited Retinal Disease Treatment Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Inherited Retinal Disease Treatment Sales by Region (2020-2031)
3.6.3 Asia Pacific Inherited Retinal Disease Treatment Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Inherited Retinal Disease Treatment Market Facts & Figures by Country
3.7.1 Latin America Inherited Retinal Disease Treatment Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Inherited Retinal Disease Treatment Sales by Country (2020-2031)
3.7.3 Latin America Inherited Retinal Disease Treatment Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Inherited Retinal Disease Treatment Market Facts & Figures by Country
3.8.1 Middle East and Africa Inherited Retinal Disease Treatment Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Inherited Retinal Disease Treatment Sales by Country (2020-2031)
3.8.3 Middle East and Africa Inherited Retinal Disease Treatment Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Inherited Retinal Disease Treatment Sales by Type (2020-2031)
4.1.1 Global Inherited Retinal Disease Treatment Sales by Type (2020-2025)
4.1.2 Global Inherited Retinal Disease Treatment Sales by Type (2026-2031)
4.1.3 Global Inherited Retinal Disease Treatment Sales Market Share by Type (2020-2031)
4.2 Global Inherited Retinal Disease Treatment Revenue by Type (2020-2031)
4.2.1 Global Inherited Retinal Disease Treatment Revenue by Type (2020-2025)
4.2.2 Global Inherited Retinal Disease Treatment Revenue by Type (2026-2031)
4.2.3 Global Inherited Retinal Disease Treatment Revenue Market Share by Type (2020-2031)
4.3 Global Inherited Retinal Disease Treatment Price by Type (2020-2031)
5 Segment by Application
5.1 Global Inherited Retinal Disease Treatment Sales by Application (2020-2031)
5.1.1 Global Inherited Retinal Disease Treatment Sales by Application (2020-2025)
5.1.2 Global Inherited Retinal Disease Treatment Sales by Application (2026-2031)
5.1.3 Global Inherited Retinal Disease Treatment Sales Market Share by Application (2020-2031)
5.2 Global Inherited Retinal Disease Treatment Revenue by Application (2020-2031)
5.2.1 Global Inherited Retinal Disease Treatment Revenue by Application (2020-2025)
5.2.2 Global Inherited Retinal Disease Treatment Revenue by Application (2026-2031)
5.2.3 Global Inherited Retinal Disease Treatment Revenue Market Share by Application (2020-2031)
5.3 Global Inherited Retinal Disease Treatment Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Spark Therapeutics
6.1.1 Spark Therapeutics Company Information
6.1.2 Spark Therapeutics Description and Business Overview
6.1.3 Spark Therapeutics Inherited Retinal Disease Treatment Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Spark Therapeutics Inherited Retinal Disease Treatment Product Portfolio
6.1.5 Spark Therapeutics Recent Developments/Updates
6.2 Novartis
6.2.1 Novartis Company Information
6.2.2 Novartis Description and Business Overview
6.2.3 Novartis Inherited Retinal Disease Treatment Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Novartis Inherited Retinal Disease Treatment Product Portfolio
6.2.5 Novartis Recent Developments/Updates
6.3 Okuvision
6.3.1 Okuvision Company Information
6.3.2 Okuvision Description and Business Overview
6.3.3 Okuvision Inherited Retinal Disease Treatment Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Okuvision Inherited Retinal Disease Treatment Product Portfolio
6.3.5 Okuvision Recent Developments/Updates
6.4 NIDEK
6.4.1 NIDEK Company Information
6.4.2 NIDEK Description and Business Overview
6.4.3 NIDEK Inherited Retinal Disease Treatment Sales, Revenue and Gross Margin (2020-2025)
6.4.4 NIDEK Inherited Retinal Disease Treatment Product Portfolio
6.4.5 NIDEK Recent Developments/Updates
6.5 Invitae
6.5.1 Invitae Company Information
6.5.2 Invitae Description and Business Overview
6.5.3 Invitae Inherited Retinal Disease Treatment Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Invitae Inherited Retinal Disease Treatment Product Portfolio
6.5.5 Invitae Recent Developments/Updates
6.6 ZEISS INTERNATIONAL
6.6.1 ZEISS INTERNATIONAL Company Information
6.6.2 ZEISS INTERNATIONAL Description and Business Overview
6.6.3 ZEISS INTERNATIONAL Inherited Retinal Disease Treatment Sales, Revenue and Gross Margin (2020-2025)
6.6.4 ZEISS INTERNATIONAL Inherited Retinal Disease Treatment Product Portfolio
6.6.5 ZEISS INTERNATIONAL Recent Developments/Updates
6.7 MeiraGTx
6.7.1 MeiraGTx Company Information
6.7.2 MeiraGTx Description and Business Overview
6.7.3 MeiraGTx Inherited Retinal Disease Treatment Sales, Revenue and Gross Margin (2020-2025)
6.7.4 MeiraGTx Inherited Retinal Disease Treatment Product Portfolio
6.7.5 MeiraGTx Recent Developments/Updates
6.8 Neurosoft
6.8.1 Neurosoft Company Information
6.8.2 Neurosoft Description and Business Overview
6.8.3 Neurosoft Inherited Retinal Disease Treatment Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Neurosoft Inherited Retinal Disease Treatment Product Portfolio
6.8.5 Neurosoft Recent Developments/Updates
6.9 Astellas Pharma
6.9.1 Astellas Pharma Company Information
6.9.2 Astellas Pharma Description and Business Overview
6.9.3 Astellas Pharma Inherited Retinal Disease Treatment Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Astellas Pharma Inherited Retinal Disease Treatment Product Portfolio
6.9.5 Astellas Pharma Recent Developments/Updates
6.10 Bionic Vision Technologies
6.10.1 Bionic Vision Technologies Company Information
6.10.2 Bionic Vision Technologies Description and Business Overview
6.10.3 Bionic Vision Technologies Inherited Retinal Disease Treatment Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Bionic Vision Technologies Inherited Retinal Disease Treatment Product Portfolio
6.10.5 Bionic Vision Technologies Recent Developments/Updates
6.11 Coave Therapeutics
6.11.1 Coave Therapeutics Company Information
6.11.2 Coave Therapeutics Description and Business Overview
6.11.3 Coave Therapeutics Inherited Retinal Disease Treatment Sales, Revenue and Gross Margin (2020-2025)
6.11.4 Coave Therapeutics Inherited Retinal Disease Treatment Product Portfolio
6.11.5 Coave Therapeutics Recent Developments/Updates
6.12 GenSight Biologics
6.12.1 GenSight Biologics Company Information
6.12.2 GenSight Biologics Description and Business Overview
6.12.3 GenSight Biologics Inherited Retinal Disease Treatment Sales, Revenue and Gross Margin (2020-2025)
6.12.4 GenSight Biologics Inherited Retinal Disease Treatment Product Portfolio
6.12.5 GenSight Biologics Recent Developments/Updates
6.13 Ionis Pharmaceuticals
6.13.1 Ionis Pharmaceuticals Company Information
6.13.2 Ionis Pharmaceuticals Description and Business Overview
6.13.3 Ionis Pharmaceuticals Inherited Retinal Disease Treatment Sales, Revenue and Gross Margin (2020-2025)
6.13.4 Ionis Pharmaceuticals Inherited Retinal Disease Treatment Product Portfolio
6.13.5 Ionis Pharmaceuticals Recent Developments/Updates
6.14 IVERIC BIO
6.14.1 IVERIC BIO Company Information
6.14.2 IVERIC BIO Description and Business Overview
6.14.3 IVERIC BIO Inherited Retinal Disease Treatment Sales, Revenue and Gross Margin (2020-2025)
6.14.4 IVERIC BIO Inherited Retinal Disease Treatment Product Portfolio
6.14.5 IVERIC BIO Recent Developments/Updates
6.15 Johnson & Johnson
6.15.1 Johnson & Johnson Company Information
6.15.2 Johnson & Johnson Description and Business Overview
6.15.3 Johnson & Johnson Inherited Retinal Disease Treatment Sales, Revenue and Gross Margin (2020-2025)
6.15.4 Johnson & Johnson Inherited Retinal Disease Treatment Product Portfolio
6.15.5 Johnson & Johnson Recent Developments/Updates
6.16 LKC Technologies
6.16.1 LKC Technologies Company Information
6.16.2 LKC Technologies Description and Business Overview
6.16.3 LKC Technologies Inherited Retinal Disease Treatment Sales, Revenue and Gross Margin (2020-2025)
6.16.4 LKC Technologies Inherited Retinal Disease Treatment Product Portfolio
6.16.5 LKC Technologies Recent Developments/Updates
6.17 Santen Pharmaceutical
6.17.1 Santen Pharmaceutical Company Information
6.17.2 Santen Pharmaceutical Description and Business Overview
6.17.3 Santen Pharmaceutical Inherited Retinal Disease Treatment Sales, Revenue and Gross Margin (2020-2025)
6.17.4 Santen Pharmaceutical Inherited Retinal Disease Treatment Product Portfolio
6.17.5 Santen Pharmaceutical Recent Developments/Updates
6.18 He Eye Hospital
6.18.1 He Eye Hospital Company Information
6.18.2 He Eye Hospital Description and Business Overview
6.18.3 He Eye Hospital Inherited Retinal Disease Treatment Sales, Revenue and Gross Margin (2020-2025)
6.18.4 He Eye Hospital Inherited Retinal Disease Treatment Product Portfolio
6.18.5 He Eye Hospital Recent Developments/Updates
6.19 Bgi Genomics
6.19.1 Bgi Genomics Company Information
6.19.2 Bgi Genomics Description and Business Overview
6.19.3 Bgi Genomics Inherited Retinal Disease Treatment Sales, Revenue and Gross Margin (2020-2025)
6.19.4 Bgi Genomics Inherited Retinal Disease Treatment Product Portfolio
6.19.5 Bgi Genomics Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Inherited Retinal Disease Treatment Industry Chain Analysis
7.2 Inherited Retinal Disease Treatment Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Inherited Retinal Disease Treatment Production Mode & Process Analysis
7.4 Inherited Retinal Disease Treatment Sales and Marketing
7.4.1 Inherited Retinal Disease Treatment Sales Channels
7.4.2 Inherited Retinal Disease Treatment Distributors
7.5 Inherited Retinal Disease Treatment Customer Analysis
8 Inherited Retinal Disease Treatment Market Dynamics
8.1 Inherited Retinal Disease Treatment Industry Trends
8.2 Inherited Retinal Disease Treatment Market Drivers
8.3 Inherited Retinal Disease Treatment Market Challenges
8.4 Inherited Retinal Disease Treatment Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
 Table 1. Global Inherited Retinal Disease Treatment Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Inherited Retinal Disease Treatment Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global Inherited Retinal Disease Treatment Market Competitive Situation by Manufacturers in 2024
 Table 4. Global Inherited Retinal Disease Treatment Sales (K Units) of Key Manufacturers (2020-2025)
 Table 5. Global Inherited Retinal Disease Treatment Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global Inherited Retinal Disease Treatment Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global Inherited Retinal Disease Treatment Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market Inherited Retinal Disease Treatment Average Price (US$/Unit) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of Inherited Retinal Disease Treatment, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Inherited Retinal Disease Treatment, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Inherited Retinal Disease Treatment, Product Type & Application
 Table 12. Global Key Manufacturers of Inherited Retinal Disease Treatment, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Inherited Retinal Disease Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Inherited Retinal Disease Treatment as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Inherited Retinal Disease Treatment Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global Inherited Retinal Disease Treatment Sales by Region (2020-2025) & (K Units)
 Table 18. Global Inherited Retinal Disease Treatment Sales Market Share by Region (2020-2025)
 Table 19. Global Inherited Retinal Disease Treatment Sales by Region (2026-2031) & (K Units)
 Table 20. Global Inherited Retinal Disease Treatment Sales Market Share by Region (2026-2031)
 Table 21. Global Inherited Retinal Disease Treatment Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global Inherited Retinal Disease Treatment Revenue Market Share by Region (2020-2025)
 Table 23. Global Inherited Retinal Disease Treatment Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global Inherited Retinal Disease Treatment Revenue Market Share by Region (2026-2031)
 Table 25. North America Inherited Retinal Disease Treatment Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America Inherited Retinal Disease Treatment Sales by Country (2020-2025) & (K Units)
 Table 27. North America Inherited Retinal Disease Treatment Sales by Country (2026-2031) & (K Units)
 Table 28. North America Inherited Retinal Disease Treatment Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America Inherited Retinal Disease Treatment Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe Inherited Retinal Disease Treatment Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe Inherited Retinal Disease Treatment Sales by Country (2020-2025) & (K Units)
 Table 32. Europe Inherited Retinal Disease Treatment Sales by Country (2026-2031) & (K Units)
 Table 33. Europe Inherited Retinal Disease Treatment Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe Inherited Retinal Disease Treatment Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific Inherited Retinal Disease Treatment Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific Inherited Retinal Disease Treatment Sales by Region (2020-2025) & (K Units)
 Table 37. Asia Pacific Inherited Retinal Disease Treatment Sales by Region (2026-2031) & (K Units)
 Table 38. Asia Pacific Inherited Retinal Disease Treatment Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific Inherited Retinal Disease Treatment Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Inherited Retinal Disease Treatment Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America Inherited Retinal Disease Treatment Sales by Country (2020-2025) & (K Units)
 Table 42. Latin America Inherited Retinal Disease Treatment Sales by Country (2026-2031) & (K Units)
 Table 43. Latin America Inherited Retinal Disease Treatment Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Inherited Retinal Disease Treatment Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa Inherited Retinal Disease Treatment Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa Inherited Retinal Disease Treatment Sales by Country (2020-2025) & (K Units)
 Table 47. Middle East and Africa Inherited Retinal Disease Treatment Sales by Country (2026-2031) & (K Units)
 Table 48. Middle East and Africa Inherited Retinal Disease Treatment Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa Inherited Retinal Disease Treatment Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global Inherited Retinal Disease Treatment Sales (K Units) by Type (2020-2025)
 Table 51. Global Inherited Retinal Disease Treatment Sales (K Units) by Type (2026-2031)
 Table 52. Global Inherited Retinal Disease Treatment Sales Market Share by Type (2020-2025)
 Table 53. Global Inherited Retinal Disease Treatment Sales Market Share by Type (2026-2031)
 Table 54. Global Inherited Retinal Disease Treatment Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global Inherited Retinal Disease Treatment Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global Inherited Retinal Disease Treatment Revenue Market Share by Type (2020-2025)
 Table 57. Global Inherited Retinal Disease Treatment Revenue Market Share by Type (2026-2031)
 Table 58. Global Inherited Retinal Disease Treatment Price (US$/Unit) by Type (2020-2025)
 Table 59. Global Inherited Retinal Disease Treatment Price (US$/Unit) by Type (2026-2031)
 Table 60. Global Inherited Retinal Disease Treatment Sales (K Units) by Application (2020-2025)
 Table 61. Global Inherited Retinal Disease Treatment Sales (K Units) by Application (2026-2031)
 Table 62. Global Inherited Retinal Disease Treatment Sales Market Share by Application (2020-2025)
 Table 63. Global Inherited Retinal Disease Treatment Sales Market Share by Application (2026-2031)
 Table 64. Global Inherited Retinal Disease Treatment Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global Inherited Retinal Disease Treatment Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global Inherited Retinal Disease Treatment Revenue Market Share by Application (2020-2025)
 Table 67. Global Inherited Retinal Disease Treatment Revenue Market Share by Application (2026-2031)
 Table 68. Global Inherited Retinal Disease Treatment Price (US$/Unit) by Application (2020-2025)
 Table 69. Global Inherited Retinal Disease Treatment Price (US$/Unit) by Application (2026-2031)
 Table 70. Spark Therapeutics Company Information
 Table 71. Spark Therapeutics Description and Business Overview
 Table 72. Spark Therapeutics Inherited Retinal Disease Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 73. Spark Therapeutics Inherited Retinal Disease Treatment Product
 Table 74. Spark Therapeutics Recent Developments/Updates
 Table 75. Novartis Company Information
 Table 76. Novartis Description and Business Overview
 Table 77. Novartis Inherited Retinal Disease Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 78. Novartis Inherited Retinal Disease Treatment Product
 Table 79. Novartis Recent Developments/Updates
 Table 80. Okuvision Company Information
 Table 81. Okuvision Description and Business Overview
 Table 82. Okuvision Inherited Retinal Disease Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 83. Okuvision Inherited Retinal Disease Treatment Product
 Table 84. Okuvision Recent Developments/Updates
 Table 85. NIDEK Company Information
 Table 86. NIDEK Description and Business Overview
 Table 87. NIDEK Inherited Retinal Disease Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 88. NIDEK Inherited Retinal Disease Treatment Product
 Table 89. NIDEK Recent Developments/Updates
 Table 90. Invitae Company Information
 Table 91. Invitae Description and Business Overview
 Table 92. Invitae Inherited Retinal Disease Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 93. Invitae Inherited Retinal Disease Treatment Product
 Table 94. Invitae Recent Developments/Updates
 Table 95. ZEISS INTERNATIONAL Company Information
 Table 96. ZEISS INTERNATIONAL Description and Business Overview
 Table 97. ZEISS INTERNATIONAL Inherited Retinal Disease Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 98. ZEISS INTERNATIONAL Inherited Retinal Disease Treatment Product
 Table 99. ZEISS INTERNATIONAL Recent Developments/Updates
 Table 100. MeiraGTx Company Information
 Table 101. MeiraGTx Description and Business Overview
 Table 102. MeiraGTx Inherited Retinal Disease Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 103. MeiraGTx Inherited Retinal Disease Treatment Product
 Table 104. MeiraGTx Recent Developments/Updates
 Table 105. Neurosoft Company Information
 Table 106. Neurosoft Description and Business Overview
 Table 107. Neurosoft Inherited Retinal Disease Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 108. Neurosoft Inherited Retinal Disease Treatment Product
 Table 109. Neurosoft Recent Developments/Updates
 Table 110. Astellas Pharma Company Information
 Table 111. Astellas Pharma Description and Business Overview
 Table 112. Astellas Pharma Inherited Retinal Disease Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 113. Astellas Pharma Inherited Retinal Disease Treatment Product
 Table 114. Astellas Pharma Recent Developments/Updates
 Table 115. Bionic Vision Technologies Company Information
 Table 116. Bionic Vision Technologies Description and Business Overview
 Table 117. Bionic Vision Technologies Inherited Retinal Disease Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 118. Bionic Vision Technologies Inherited Retinal Disease Treatment Product
 Table 119. Bionic Vision Technologies Recent Developments/Updates
 Table 120. Coave Therapeutics Company Information
 Table 121. Coave Therapeutics Description and Business Overview
 Table 122. Coave Therapeutics Inherited Retinal Disease Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 123. Coave Therapeutics Inherited Retinal Disease Treatment Product
 Table 124. Coave Therapeutics Recent Developments/Updates
 Table 125. GenSight Biologics Company Information
 Table 126. GenSight Biologics Description and Business Overview
 Table 127. GenSight Biologics Inherited Retinal Disease Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 128. GenSight Biologics Inherited Retinal Disease Treatment Product
 Table 129. GenSight Biologics Recent Developments/Updates
 Table 130. Ionis Pharmaceuticals Company Information
 Table 131. Ionis Pharmaceuticals Description and Business Overview
 Table 132. Ionis Pharmaceuticals Inherited Retinal Disease Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 133. Ionis Pharmaceuticals Inherited Retinal Disease Treatment Product
 Table 134. Ionis Pharmaceuticals Recent Developments/Updates
 Table 135. IVERIC BIO Company Information
 Table 136. IVERIC BIO Description and Business Overview
 Table 137. IVERIC BIO Inherited Retinal Disease Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 138. IVERIC BIO Inherited Retinal Disease Treatment Product
 Table 139. IVERIC BIO Recent Developments/Updates
 Table 140. Johnson & Johnson Company Information
 Table 141. Johnson & Johnson Description and Business Overview
 Table 142. Johnson & Johnson Inherited Retinal Disease Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 143. Johnson & Johnson Inherited Retinal Disease Treatment Product
 Table 144. Johnson & Johnson Recent Developments/Updates
 Table 145. LKC Technologies Company Information
 Table 146. LKC Technologies Description and Business Overview
 Table 147. LKC Technologies Inherited Retinal Disease Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 148. LKC Technologies Inherited Retinal Disease Treatment Product
 Table 149. LKC Technologies Recent Developments/Updates
 Table 150. Santen Pharmaceutical Company Information
 Table 151. Santen Pharmaceutical Description and Business Overview
 Table 152. Santen Pharmaceutical Inherited Retinal Disease Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 153. Santen Pharmaceutical Inherited Retinal Disease Treatment Product
 Table 154. Santen Pharmaceutical Recent Developments/Updates
 Table 155. He Eye Hospital Company Information
 Table 156. He Eye Hospital Description and Business Overview
 Table 157. He Eye Hospital Inherited Retinal Disease Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 158. He Eye Hospital Inherited Retinal Disease Treatment Product
 Table 159. He Eye Hospital Recent Developments/Updates
 Table 160. Bgi Genomics Company Information
 Table 161. Bgi Genomics Description and Business Overview
 Table 162. Bgi Genomics Inherited Retinal Disease Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 163. Bgi Genomics Inherited Retinal Disease Treatment Product
 Table 164. Bgi Genomics Recent Developments/Updates
 Table 165. Key Raw Materials Lists
 Table 166. Raw Materials Key Suppliers Lists
 Table 167. Inherited Retinal Disease Treatment Distributors List
 Table 168. Inherited Retinal Disease Treatment Customers List
 Table 169. Inherited Retinal Disease Treatment Market Trends
 Table 170. Inherited Retinal Disease Treatment Market Drivers
 Table 171. Inherited Retinal Disease Treatment Market Challenges
 Table 172. Inherited Retinal Disease Treatment Market Restraints
 Table 173. Research Programs/Design for This Report
 Table 174. Key Data Information from Secondary Sources
 Table 175. Key Data Information from Primary Sources
 Table 176. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Inherited Retinal Disease Treatment
 Figure 2. Global Inherited Retinal Disease Treatment Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Inherited Retinal Disease Treatment Market Share by Type: 2024 & 2031
 Figure 4. Gene Therapy Product Picture
 Figure 5. Artificial Retina Product Picture
 Figure 6. Neuroprotectant Product Picture
 Figure 7. Global Inherited Retinal Disease Treatment Market Value by Application (2020-2031) & (US$ Million)
 Figure 8. Global Inherited Retinal Disease Treatment Market Share by Application: 2024 & 2031
 Figure 9. Hospital
 Figure 10. Clinic
 Figure 11. Global Inherited Retinal Disease Treatment Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 12. Global Inherited Retinal Disease Treatment Market Size (2020-2031) & (US$ Million)
 Figure 13. Global Inherited Retinal Disease Treatment Sales (2020-2031) & (K Units)
 Figure 14. Global Inherited Retinal Disease Treatment Average Price (US$/Unit) & (2020-2031)
 Figure 15. Inherited Retinal Disease Treatment Report Years Considered
 Figure 16. Inherited Retinal Disease Treatment Sales Share by Manufacturers in 2024
 Figure 17. Global Inherited Retinal Disease Treatment Revenue Share by Manufacturers in 2024
 Figure 18. Global 5 and 10 Largest Inherited Retinal Disease Treatment Players: Market Share by Revenue in Inherited Retinal Disease Treatment in 2024
 Figure 19. Inherited Retinal Disease Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 20. Global Inherited Retinal Disease Treatment Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 21. North America Inherited Retinal Disease Treatment Sales Market Share by Country (2020-2031)
 Figure 22. North America Inherited Retinal Disease Treatment Revenue Market Share by Country (2020-2031)
 Figure 23. United States Inherited Retinal Disease Treatment Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 24. Canada Inherited Retinal Disease Treatment Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 25. Europe Inherited Retinal Disease Treatment Sales Market Share by Country (2020-2031)
 Figure 26. Europe Inherited Retinal Disease Treatment Revenue Market Share by Country (2020-2031)
 Figure 27. Germany Inherited Retinal Disease Treatment Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 28. France Inherited Retinal Disease Treatment Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 29. U.K. Inherited Retinal Disease Treatment Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 30. Italy Inherited Retinal Disease Treatment Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 31. Russia Inherited Retinal Disease Treatment Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 32. Asia Pacific Inherited Retinal Disease Treatment Sales Market Share by Region (2020-2031)
 Figure 33. Asia Pacific Inherited Retinal Disease Treatment Revenue Market Share by Region (2020-2031)
 Figure 34. China Inherited Retinal Disease Treatment Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 35. Japan Inherited Retinal Disease Treatment Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 36. South Korea Inherited Retinal Disease Treatment Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 37. India Inherited Retinal Disease Treatment Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 38. Australia Inherited Retinal Disease Treatment Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 39. China Taiwan Inherited Retinal Disease Treatment Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. Southeast Asia Inherited Retinal Disease Treatment Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. Latin America Inherited Retinal Disease Treatment Sales Market Share by Country (2020-2031)
 Figure 42. Latin America Inherited Retinal Disease Treatment Revenue Market Share by Country (2020-2031)
 Figure 43. Mexico Inherited Retinal Disease Treatment Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 44. Brazil Inherited Retinal Disease Treatment Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 45. Argentina Inherited Retinal Disease Treatment Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 46. Middle East and Africa Inherited Retinal Disease Treatment Sales Market Share by Country (2020-2031)
 Figure 47. Middle East and Africa Inherited Retinal Disease Treatment Revenue Market Share by Country (2020-2031)
 Figure 48. Turkey Inherited Retinal Disease Treatment Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 49. Saudi Arabia Inherited Retinal Disease Treatment Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 50. UAE Inherited Retinal Disease Treatment Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 51. Global Sales Market Share of Inherited Retinal Disease Treatment by Type (2020-2031)
 Figure 52. Global Revenue Market Share of Inherited Retinal Disease Treatment by Type (2020-2031)
 Figure 53. Global Inherited Retinal Disease Treatment Price (US$/Unit) by Type (2020-2031)
 Figure 54. Global Sales Market Share of Inherited Retinal Disease Treatment by Application (2020-2031)
 Figure 55. Global Revenue Market Share of Inherited Retinal Disease Treatment by Application (2020-2031)
 Figure 56. Global Inherited Retinal Disease Treatment Price (US$/Unit) by Application (2020-2031)
 Figure 57. Inherited Retinal Disease Treatment Value Chain
 Figure 58. Channels of Distribution (Direct Vs Distribution)
 Figure 59. Bottom-up and Top-down Approaches for This Report
 Figure 60. Data Triangulation
 Figure 61. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Accenture

SIMILAR REPORTS

RELATED REPORTS

Global High Acuity Care Service Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-5D18285
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global mHealth (Mobile Health) Services Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-18B6151
Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Resin Lenses Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-21S7871
Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Mobile Medical Imaging Services Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-16Q6154
Thu Sep 11 00:00:00 UTC 2025

Add to Cart